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VASOACTIVE INTESTINAL PEPTIDE
(VIP): NEUROPROTECTION AND
SYNAPSE FORMATION
This review is a selected overview of the
chosen subject. As, I have recently sum-
marized my work on VIP (Gozes, 2008),
I will describe here only selected topics
focusing on the GPCR connection of the
VIP-regulated protein, activity-dependent
neuroprotective protein (ADNP) (Gozes,
2007).
In the mid 1980s we were the first to
clone the gene encoding the 28 amino
acid neuropeptide, vasoactive intestinal
peptide (VIP) (Bodner et al., 1985).
This allowed us to follow up VIP gene
expression in the brain showing devel-
opmental increases at the time of post-
natal synapse formation and glial expan-
sion (Gozes et al., 1987). Given the
increased expression of VIP at the time
of synapse formation and glial expansion,
we hypothesized a developmental role
for the peptide—associated with synap-
togenesis and neuroprotection. Follow-
up studies by the laboratory of Douglas
Brenneman indeed showed that VIP pro-
vided neuroprotection through glial cells
(Brenneman et al., 1987). We teamed up
to show together with the group of Ronald
McKay that VIP enhances synapse forma-
tion through glial cell activation (Blondel
et al., 2000).
Together with the late Frank Baldino,
we showed extensive VIP mRNA expres-
sion in the brain, for example, in the
suprachiasmatic nucleus (SCN) (Card
et al., 1988), an area regulating diurnal
rhythms. Our further studies utiliz-
ing our VIP hybrid antagonist showed
that VIP function during development
was required for maintenance of diur-
nal rhythmicity (Gozes et al., 1995).
These findings were later confirmed by
knocking out either VIP (Loh et al.,
2011), or the VIP receptor VPAC2
(Harmar et al., 2002), which brings us
to part of the subject of this review,
GPCRs.
VIP RECEPTORS
We have recently reviewed the current sta-
tus of research on VIP receptors (Harmar
et al., 2012). In short, VIP and pituitary
adenylate cyclase-activating polypeptide
(PACAP) are members of a superfamily
of structurally related peptide hormones
that includes glucagon, glucagon-like pep-
tides, secretin, gastric inhibitory peptide
(GIP) and growth hormone-releasing hor-
mone (GHRH). VIP and PACAP exert
their actions through three GPCRs—
PAC1, VPAC1 and VPAC2—belonging
to class B (also referred to as class II,
or secretin receptor-like GPCRs). PAC1
receptors are selective for PACAP, whereas
VPAC1 and VPAC2 respond to both VIP
and PACAP with high affinity (Harmar
et al., 2012). As indicated above, VPAC2
was associated with diurnal rhythmicity
(Harmar et al., 2002) as well as astroge-
nesis (Zupan et al., 1998). Other func-
tions, including association with can-
cer propagation and immunomodulation
have been extensively reviewed (as cited
above).
VIP RECEPTORS AND
NEUROPROTECTION, OUR POINT OF
VIEW
Prior to the molecular cloning of VIP
and PACAP receptors, binding and
displacement assays coupled to functional
assays suggested high affinity binding for
VIP on glial cells (astrocytes)—associated
with the release of neuroprotective pro-
teins and low affinity binding to astrocytes,
associated with cAMP formation (Gozes
et al., 1991). With the available VPAC1,
VPAC2, and PAC1 clones (including the
alternatively spliced PAC1 receptors), we
have used antisense oligodeoxynucleotides
specific for each of the then known recep-
tor subtypes to identify receptors involved
in neuroprotection. Our data showed
that one of the PAC1 splice variants,
the hop2-like receptor is a receptor that
mediates neuroprotection (Ashur-Fabian
et al., 1997). The PAC1 cDNA was cloned
from rat cerebral astrocytes. Using genetic
manipulation we obtained the hop2 splice
variant and expressed it in COS-7 cells.
Results showed that VIP bound the cloned
hop2 splice variant (Pilzer and Gozes,
2006). Stearyl-neurotensin (6–11) VIP (7–
28) (SNH), an antagonist for VIP, was also
found to bind hop2. Other studies have
shown that this particular antagonist that
we have developed (Gozes et al., 1995)
binds to all know VIP receptors (Moody
et al., 2002). In addition, VIP protected
COS-7 cells expressing hop2 from oxida-
tive stress. Parallel assays demonstrated
that VIP increased cAMP accumulation in
COS-7 cells expressing hop2. These results
support the hypothesis that hop2 medi-
ates some of the cytoprotective effects
attributed to VIP (Pilzer and Gozes,
2006).
However, the study cited above did
not address the requirement for astrocytes
for VIP neuroprotection, suggesting addi-
tional players.
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VIP STIMULATE ASTROCYTE
SECRETION OF GROWTH FACTORS
We teamed up together with Douglas
Brenneman to isolate novel growth factors
from VIP-stimulated astrocyte condi-
tioned media. Our first attempt included
sequential chromatography coupled to
functional assays of neuroprotection,
yielding activity-dependent neurotrophic
factor (ADNF) (Brenneman and Gozes,
1996). This study took us to three direc-
tions: (1) identification of an active
peptide site within ADNF—potential
future therapeutic; (2) production of
antibodies against ADNF as tools for func-
tional studies and (3) use of the antibodies
for expression cloning toward the identifi-
cation of novel ADNF-like molecules, thus
cloning ADNP (Bassan et al., 1999). We
have further identified ADNP immunore-
activity in astrocyte conditioned medium,
which was increased upon exposure to VIP
(Furman et al., 2004).
GPCR INVOLVEMENT IN ADNP
EXPRESSION
Using VIP analogues specific for the
VPAC1 and the VPAC2 receptors, we
discovered that VIP-induced changes in
ADNP expression in astrocytes via the
VPAC2 receptor. The constitutive synthe-
sis of ADNP and VPAC2 was shown to be
age-dependent and increased as the astro-
cyte culture developed. The VIP-related
peptide, PACAP also induced changes in
ADNP expression. The apparent change-
induced by VIP and PACAP on ADNP
expression were developmentally depen-
dent, and while stimulating expression in
young astrocytes (Bassan et al., 1999), an
inhibition was demonstrated in older cul-
tures suggesting that VIP, PACAP, and
the VPAC2 receptor may all contribute to
the regulation of ADNP gene expression
in the developing astrocyte (Zusev and
Gozes, 2004).
Parallel studies by the discoverer of
PACAP, the late Akira Arimura, showed
that when PACAP38 was added to mouse
neuroglial cultures, it induced ADNP
mRNA expression in a bimodal fashion
at subpico- and nanomolar concentrations
with greater response at subpicomolar
level. The response was attenuated by a
PAC1 receptor antagonist at both con-
centrations and by a VPAC1 receptor
antagonist at nanomolar concentration
only. An IP3/PLC inhibitor attenuated
the response at both concentrations of
PACAP38, but a MAPK inhibitor had
no effect. A PKA inhibitor suppressed
the response at nanomolar concentration
only. The findings suggest that ADNP
expression is mediated through multiple
receptors and signaling pathways that
are regulated by different concentrations
of PACAP (Nakamachi et al., 2006) as
well as VIP. A further study showed
that ADNP-immunoreactive cells in the
cerebral cortex were multi-polar-shaped
and co-immunostained with the astro-
cyte marker, glial fibrillary acidic pro-
tein (GFAP). ADNP-immunoreactive cells
in the cerebellum were found to sur-
round Purkinje cells and showed GFAP
immunoreactivity. In contrast, ADNP-
immunoreactive cells in the hippocam-
pus and septum were round in shape and
co-immunostained with neuron-specific
enolase (NSE). Importantly, all of the
ADNP-immunopositive cells co-localized
with PAC1 immunoreactivity. The obser-
vations suggest that ADNP is expressed
in both astrocytes and neurons, and
that ADNP expression may be regulated
in part by PACAP (Nakamachi et al.,
2008).
Using bioinformatics analysis, we have
identified an ADNP family member which
we have named, ADNP2 (Zamostiano
et al., 2001; Kushnir et al., 2008).
To evaluate the impact of VIP expres-
sion in vivo on ADNP and the related pro-
tein ADNP2, we examined gene expres-
sion in adult wild-type (VIP+/+) and VIP
null (VIP−/−) offspring of VIP deficient
mothers (VIP+/−) comparing them to
wild-type offspring of wild-type mothers.
Quantitative real time polymerase chain
reaction (PCR) revealed regionally spe-
cific reductions of ADNP mRNA in the
brains of VIP−/− mice compared with
the brains of wild-type offspring of a
wild-type mother. ADNP was significantly
reduced in the cortex and hypothalamus
of VIP−/− mice, but not in the hip-
pocampus or thalamus. ADNP2 exhibited
a similar pattern but reached a statistically
significant reduction only in the hypotha-
lamus. The RNA transcripts for ADNP and
ADNP2 also tended to be reduced in the
cortex and hippocampus of the wild-type
littermates of the VIP−/− mice, indicat-
ing that the VIP genotype of the mother
may have had an impact on the ADNP
expression of her offspring, regardless of
their own VIP genotype. Thus, VIP regu-
lates brain ADNP expression in a region-
ally specific manner and both maternal
and offspring VIP genotype may influ-
ence ADNP expression in the brain (Giladi
et al., 2007).
CLINICAL IMPLICATIONS
Recent genetic studies titled: duplications
of the neuropeptide receptor gene VPAC2
confer significant risk for schizophrenia
implicated the VPAC2 receptor in sus-
ceptibility to schizophrenia. Further stud-
ies implicated the PAC1 receptor and
PACAP in post-traumatic stress disorder
as recently reviewed (Harmar et al., 2012).
In this respect, we found deregula-
tion of ADNP/ADNP2 in the postmortem
hippocampus of schizophrenia patients
(Dresner et al., 2011) and correlated with
disease duration.
Other findings associated reduced
ADNP expression to the progression of
multiple sclerosis and increased pro-
inflammatory markers (Braitch et al.,
2009), and potential modulation by the
ADNP derived drug candidate davunetide
(NAP).
While VIP may present a dual func-
tion in the regulation of multiple sclero-
sis (Abad et al., 2010; Loh et al., 2011),
it should be borne in mind that ADNP
regulation, while in part associated with
VIP and PACAP, is regulated by other
control mechanisms. While VIP knockout
exhibited a subtle phenotype (e.g., Abad
et al., 2010; Loh et al., 2011) and VIP
over expression, eventually led to down-
regulation of activity with learning deficits
(Gozes et al., 1993), ADNP knockout is
lethal at embryonic time of brain for-
mation, implicating ADNP as crucial for
brain formation (Pinhasov et al., 2003;
Mandel et al., 2007). Interestingly, VIP
is suggested as a growth factor to the
developing embryo (Gressens et al., 1993,
1994). Furthermore, partial ADNP defi-
ciency leads to cognitive and social dys-
function (Vulih-Shultzman et al., 2007),
similar to partial deficiency in VIP func-
tions (Glowa et al., 1992; Gozes et al.,
1993; Hill et al., 2007). This deficiency
can be also associated with deficiency at
the cellular level, with ADNP knockdown
(or partial deficiency) associated with
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blocked neurite outgrowth (Mandel et al.,
2008) and reduced glial neurotrophic
milieu (Pascual and Guerri, 2007; Vulih-
Shultzman et al., 2007) and with VIP
blockade resulting in neuronal damage
(Hill et al., 1994) and inhibition of synap-
togenesis (Blondel et al., 2000).
In the case of ADNP, davunetide, an
eight amino acid peptide snippet of ADNP
is in phase 2/3 clinical trials in a severe
neurodegeneration, progressive supranu-
clear palsy (PSP) (Gold et al., 2012).
FUTURE PERSPECTIVE
While this review focused on VIP and
ADNP, from my point of view, it should
be taken into consideration that we
have developed a family of peptide
hybrids/fragments and lipophilic VIP
analogs, agonists and antagonists (Gozes
et al., 1995), with activities ranging
from neurtrophism/neurodevelopment
neuroprotection (Gozes et al., 1999)
to stimulation of sexual/social func-
tion and cancer growth inhibition. The
precise GPCR involvement in these ana-
logues activities remains to be elucidated
(Gourlet et al., 1998; Moody et al.,
2002). Interestingly, ADNP expression
was shown to be reduced as a conse-
quence of ischemia in tissue culture, and
this was inhibited by treatment with the
neuroprotective lypophilic VIP analog
Stearyl-Norleucine17VIP(7–28) (SNV)
(Sigalov et al., 2000), awaiting future
development.
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